Comparative Pharmacology
Head-to-head clinical analysis: TYZINE versus VISINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TYZINE versus VISINE.
TYZINE vs VISINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazoline sympathomimetic amine that stimulates alpha-2 adrenergic receptors in the nasal vasculature, producing vasoconstriction and reducing nasal congestion.
Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.
Instill 1-2 drops of 0.1% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day.
1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours; clinically, this supports dosing every 8-12 hours.
Approximately 1-2 hours for ocular absorption; systemic half-life not clinically relevant due to low systemic absorption
Renal elimination of unchanged drug and metabolites accounts for approximately 50% of the dose; fecal elimination is minimal.
Primarily renal as unchanged drug and metabolites; minor biliary/fecal elimination (<10%)
Category C
Category C
Ophthalmic Decongestant
Ophthalmic Decongestant